Dr Michael Hill
Laboratory Scientific Director
- MRC PHRU Director of Laboratories
Dr Hill joined CTSU in 2009 and is the Laboratory Scientific Director of the NDPH Wolfson Laboratories. He has a background in population-based studies and functional studies associated with respiratory and cardiovascular disease. He manages a team of 40 research and technical staff and is responsible for senior strategic oversight of all aspects of laboratory research within NDPH.
Dr Hill works closely with NDPH’s principal investigators, providing central laboratory support for their clinical trials and observational studies ensuring the scientific integrity of the laboratory work.
Research interests include investigating new biochemical markers and validating analytical methods suitable for large-scale research. NDPH Wolfson Laboratories are a UKAS accredited testing laboratory (ISO 17025:2005; No. 2799) with extensive computer automation and a particular expertise in developing reliable high-throughput methods of analysis in clinical chemistry and protein biomarkers.
Previous history: Dr Hill gained his DPhil at the University of Oxford in 1992 and continued his post-doctoral studies at the Nuffield Department of Clinical Medicine, Oxford and The Wellcome Trust Centre for Human Genetics, Oxford. In 1998, he joined the Division of Medicine at University College London where he led a research group.
Diabetes and premature mortality in Mexico City: Blood-based prospective study of 15,000 Mexican adults with 12 years’ mortality follow-up
Herrington W. et al, (2017), None
Optimum dose of vitamin D for disease prevention in older people: BEST-D trial of vitamin D in primary care.
Hin H. et al, (2017), Osteoporos Int, 28, 841 - 851
Diabetes and Cause-Specific Mortality in Mexico City.
Alegre-Díaz J. et al, (2016), N Engl J Med, 375, 1961 - 1971
Effect of Processing Delay and Storage Conditions on Urine Albumin-to-Creatinine Ratio.
Herrington W. et al, (2016), Clin J Am Soc Nephrol, 11, 1794 - 1801
A phenome-wide association study of a lipoprotein-associated phospholipase A2 loss-of-function variant in 90 000 Chinese adults.
Millwood IY. et al, (2016), Int J Epidemiol, 45, 1588 - 1599